Bolt Biotherapeutics (BOLT) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($12.8 million vs $12.6 million), about 1.0 times the size. Seres Therapeutics converts more of its revenue into profit, with a net margin of 721.9% versus -433.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLT | MCRB |
|---|---|---|
| Share price | $4.91 | $1.24 |
| Market cap | $12.80M | $12.64M |
| 1-day change | -2.96% | -6.77% |
| EPS (TTM) | $-14.00 | $-5.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.70M | $789.00K |
| Revenue growth (YoY) | +0.07% | — |
| Net income (latest FY) | $-33.38M | $5.70M |
| Operating margin | -469.30% | -11910.14% |
| Net margin | -433.74% | 721.93% |
| 52-week high | $7.78 | $18.86 |
| 52-week low | $3.10 | $1.20 |
| Distance from 52-week high | -36.89% | -93.43% |
| Analyst consensus | none | none |
| Avg. price target upside | +490.63% | +1270.97% |
| Average volume | 257.43K | 74.83K |
| Shares outstanding | 2.61M | 10.20M |
| Employees | 23 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Seres Therapeutics is more profitable, keeping 721.9 cents of every revenue dollar as net income versus -433.7 cents for Bolt Biotherapeutics.
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
BOLT vs MCRB FAQ
Which is bigger, Bolt Biotherapeutics or Seres Therapeutics?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $12.80M compared with $12.64M for Seres Therapeutics (MCRB).
Are Bolt Biotherapeutics and Seres Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.